Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NRM6
UPID:
I17RB_HUMAN
Alternative names:
Cytokine receptor-like 4; IL-17 receptor homolog 1; Interleukin-17B receptor
Alternative UPACC:
Q9NRM6; Q9BPZ0; Q9NRL4; Q9NRM5
Background:
Interleukin-17 receptor B, also known as Cytokine receptor-like 4, IL-17 receptor homolog 1, and Interleukin-17B receptor, plays a pivotal role in immune response. It acts as a receptor for the pro-inflammatory cytokines IL17B and IL17E, which are crucial in the body's defense mechanisms. This receptor's involvement in controlling the growth and/or differentiation of hematopoietic cells highlights its significance in maintaining hematopoietic balance and immune system regulation.
Therapeutic significance:
Understanding the role of Interleukin-17 receptor B could open doors to potential therapeutic strategies. Its critical function in mediating inflammatory responses and hematopoietic cell regulation presents a unique opportunity for developing targeted treatments in immune-related disorders.